These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2806473)

  • 1. Sialyltransferase activity in plasma cells of multiple myeloma.
    Cohen AM; Allalouf D; Djaldetti M; Weigl K; Lehrer N; Levinsky H
    Eur J Haematol; 1989 Sep; 43(3):191-4. PubMed ID: 2806473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sialyltransferase activity and sialic acid levels in multiple myeloma and monoclonal gammopathy.
    Cohen AM; Allalouf D; Bessler H; Djaldetti M; Malachi T; Levinsky H
    Eur J Haematol; 1989 Mar; 42(3):289-92. PubMed ID: 2924892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scoring system for cytochemical betaglucuronidase activity in normal bone marrow plasmacells and myelomacells.
    Van der Planken M; Berneman Z; Peetermans M
    Acta Clin Belg; 1982; 37(2):80-3. PubMed ID: 7113573
    [No Abstract]   [Full Text] [Related]  

  • 4. Sialyltransferase activity in AF10 myeloma cell line.
    Cohen AM; Allalouf D; Wacks T; Lehrer N; Levinsky H
    Biochem Med Metab Biol; 1990 Oct; 44(2):101-5. PubMed ID: 2252611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasma cell acid phosphatase in the differential diagnosis of monoclonal gammopathies].
    Milanesi B; Tafuri C; Perini M; Rota G; Peretti P
    Quad Sclavo Diagn; 1984 Jun; 20(2):149-54. PubMed ID: 6528014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histochemical study on plasma cells.
    Suzuki A; Shibata A; Onodera S; Miura AB; Sakamoto S
    Tohoku J Exp Med; 1969 Jan; 97(1):1-9. PubMed ID: 4306171
    [No Abstract]   [Full Text] [Related]  

  • 7. Myeloma bone marrow acid phosphatase staining: a correlative study of 38 patients.
    Bataille R; Durie BG; Sany J; Salmon SE
    Blood; 1980 May; 55(5):802-5. PubMed ID: 6767509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytochemical demonstration of beta-glucuronidase and beta-acetylglucosaminidase in plasmacytoma].
    Löffler H; Platt D; Platt M
    Klin Wochenschr; 1970 Apr; 48(8):480-2. PubMed ID: 5519401
    [No Abstract]   [Full Text] [Related]  

  • 9. 5'-nucleotidase activity in myeloma cells.
    El-Mohandes EA; Hayhoe FG
    Clin Lab Haematol; 1983; 5(3):265-9. PubMed ID: 6317278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vacuolated plasma cells in multiple myeloma.
    Kanoh T; Yasuda N; Takamatsu T; Uchino H
    Tohoku J Exp Med; 1986 Apr; 148(4):361-4. PubMed ID: 3526637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum sialyltransferase and fucosyltransferase activities in patients with multiple myeloma.
    Frithz G; Ronquist G; Ericsson P
    Eur J Cancer Clin Oncol; 1985 Aug; 21(8):913-7. PubMed ID: 4043176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cell acid phosphatase score in multiple myeloma and related disorders.
    Hoffmann JJ; Breed WP; Swaak-Lammers N
    Br J Haematol; 1985 Jan; 59(1):67-72. PubMed ID: 3970852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma.
    Terpstra WE; Lokhorst HM; Blomjous F; Meuwissen OJ; Dekker AW
    Br J Haematol; 1992 Sep; 82(1):46-9. PubMed ID: 1419801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.
    Bret C; Hose D; Reme T; Kassambara A; Seckinger A; Meissner T; Schved JF; Kanouni T; Goldschmidt H; Klein B
    Exp Hematol; 2011 May; 39(5):546-557.e8. PubMed ID: 21316416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cytoplasmic 5'nucleotidase for differentiating malignant from benign monoclonal gammopathies.
    Majumdar G; Heard SE; Singh AK
    J Clin Pathol; 1990 Nov; 43(11):891-2. PubMed ID: 2262558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma.
    Vacca A; Ribatti D; Roccaro AM; Ria R; Palermo L; Dammacco F
    Acta Haematol; 2001; 106(4):162-9. PubMed ID: 11815713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
    Pasqualetti P; Colantonio D; Casale R
    Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ATPase activity of bone marrow plasmocytes and its value in the diagnosis of myeloma. Preliminary note].
    Lejeune F; Gérard-Hetfleis E; Henon P; Turpin F; Lecoq D; Lortholary P
    Pathol Biol (Paris); 1972 May; 20(9):485-91. PubMed ID: 4261061
    [No Abstract]   [Full Text] [Related]  

  • 19. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.
    Boccadoro M; Gallamini A; Fruttero A; Gavarotti P; Redoglia V; Buffa F; Ruá S; Pileri A
    J Clin Oncol; 1985 Nov; 3(11):1503-7. PubMed ID: 4056842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.